Skip to main content
SpringerLink
Log in

Malignant Peritoneal Mesothelioma

  • Chapter
  • First Online:
Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond

  • 828 Accesses

Abstract

One of the first descriptions of malignant peritoneal mesothelioma (MPM) was in a case report published 100 years ago [1]. In 1972, Moertel published a review of MPM and described the clinical presentation, histological features, and biological behavior of 169 patients [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. Med Gen Med. 2007;9:32.

    Google Scholar 

  2. Moertel CG. Peritoneal mesothelioma. Gastroenterology. 1972;63(2):346–50.

    CAS  PubMed  Google Scholar 

  3. Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK, Johnston FM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686–93.

    Article  PubMed  Google Scholar 

  4. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39:576–88.

    Article  PubMed  Google Scholar 

  5. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–21.

    Article  PubMed  Google Scholar 

  6. Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. EJSO. 2006;32:686–91.

    Article  CAS  PubMed  Google Scholar 

  7. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985–90.

    Article  CAS  PubMed  Google Scholar 

  8. Wagner JC, Gilson JC, Berry G, Timbrell V. Epidemiology of asbestos cancers. Br Med Bull. 1971;27(1):71–6.

    Article  CAS  PubMed  Google Scholar 

  9. Spirtas R, Heineman EF, Bernstein L, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med. 1994;51:804–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Newhouse ML, Thopson H. Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area. 1965. Br J Ind Med. 1993;50:769–78.

    CAS  PubMed  Google Scholar 

  11. Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg. 2000;44:565–601.

    Article  CAS  PubMed  Google Scholar 

  12. Peterson JT, Greenberg SD, Buffler PA. Non-asbestos-related malignant mesothelioma: a review. Cancer. 1984;54:951–60.

    Article  PubMed  Google Scholar 

  13. Lin RT, Takahashi K, Karjalainen A, Hoshuyama T, Wilson D, Kameda T, Chan CC, Wen CP, Furuya S, Higashi T, Chien LC, Ohtaki M. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet. 2017;369(9564):844–9.

    Google Scholar 

  14. Weill H, Hughes JM, Chrug AM. Changing trends in US mesothelioma incidence. Occup Environ Med. 2004;61:438–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Stock RJ, YS F, Carter JR. Malignant peritoneal mesothelioma following radiotherapy for seminoma of the testis. Cancer. 1979;44:914–9.

    Article  CAS  PubMed  Google Scholar 

  16. Baris YI, Grandjean P. Prospective study of mesothelioma mortality in Turkish villages with exposure to fibrous zeolite. J Natl Cancer Inst. 2006;98(6):414–7.

    Article  CAS  PubMed  Google Scholar 

  17. Hueper WC. Cancer induction by polyurethane and polysilicone plastics. J Natl Cancer Inst. 1964;33:1005–27.

    CAS  PubMed  Google Scholar 

  18. Shivapurkar N, Weithege T, Wistuba II, Milchgrub S, Muller KM, Gazdar AF. Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas. Int J Cancer. 2000;85:743–5.

    Article  CAS  PubMed  Google Scholar 

  19. Alakus H, Yost SE, Woo B, French R, Lin GY, Jepsen K, Frazer KA, Lowy AM, Harismendy O. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med. 2015;13:122.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Park JY, Kim KW, Kown HJ, Park MS, Kwon GU, Jun SY, Yu ES. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR. 2009;191:814–21.

    Article  Google Scholar 

  21. Alexander HR, Burk AP. Diagnosis and management of patients with malignant peritoneal mesothelioma. J Gastrointest Oncol. 2016;7(1):79–86.

    PubMed  PubMed Central  Google Scholar 

  22. Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol. 1981;8(3):313–20.

    CAS  PubMed  Google Scholar 

  23. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7.

    Article  CAS  PubMed  Google Scholar 

  24. Reuter K, Raptopoulos V, Reale F, Krolikowski FJ, D’Orsi CJ, Graham S, Smith EH. Diagnosis of peritoneal mesothelioma: computed tomography, sonography, and fine-needle aspiration biopsy. AJR. 1983;140(6):1189–94.

    Article  CAS  PubMed  Google Scholar 

  25. Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;103(4):839–49.

    Article  PubMed  Google Scholar 

  26. Sharma H, Bell I, Schofield J, Bird G. Primary peritoneal mesothelioma: case series and literature review. Clin Res Hepatol Gastroenterol. 2011;35(1):55–9.

    Article  CAS  PubMed  Google Scholar 

  27. Low RN, Barone RM. Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2012;19:1394–401.

    Article  PubMed  Google Scholar 

  28. Hassan R, Remaely AT, Sampson ML, Zhang J, Cox DD, Pingpak J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantification of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12(2):447–53.

    Article  CAS  PubMed  Google Scholar 

  29. Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, Deraco M. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14:500–8.

    Article  PubMed  Google Scholar 

  30. Sebbag G, Yan H, Shmookler M, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87:1587–93.

    Article  CAS  PubMed  Google Scholar 

  31. Husain A, Colby TV, Travis WD, Wick M. Guidelines for pathologic diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2009;133:1317–31.

    PubMed  Google Scholar 

  32. Lee M, Alexander HR, Burke A. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy. Pathology. 2013;45(5):464–73.

    Article  CAS  PubMed  Google Scholar 

  33. Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR, Churg A, Dacic S, Fraire A, Galateau-Salle F, Gibbs A, Gown A, Hammar S, Litzky L, Marchevsky AM, Nicholson AG, Roggli V, Travis WD, Wick M, International Mesothelioma Interest Group. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137(5):647–67.

    Article  PubMed  Google Scholar 

  34. Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20:215–20.

    Article  CAS  PubMed  Google Scholar 

  35. Husain AN, Miraza MK, Gibbs A, Hiroshima K, Chi Y, Boumendjel R, Stang N, Krausz T, Galateau-Salle F. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas. In international collaborative study. Lung Cancer. 2014;83:324–8.

    Article  PubMed  Google Scholar 

  36. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.

    Article  CAS  PubMed  Google Scholar 

  37. Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Peritoneal Surface Oncology Group. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117(9):1855–63.

    Article  PubMed  Google Scholar 

  38. Chua TC, Chong CH, Morris DL. Peritoneal mesothelioma: current status and future directions. Surg Oncol Clin N Am. 2012;21:635–43.

    Article  PubMed  Google Scholar 

  39. Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol. 2011;103:822–31.

    Article  PubMed  Google Scholar 

  40. Eltabbakh GH, Piver MS, Hempling RE, Recio FO. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.

    Article  CAS  PubMed  Google Scholar 

  41. Yan TD, Deraco M, Barrati D, Kusamua S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Moahmed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.

    Article  PubMed  Google Scholar 

  42. Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093–100.

    Article  PubMed  Google Scholar 

  43. Miura JT, Johnston FM, Gamblin TC, Turaga KK. Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol. 2014;21:3947–53.

    Article  PubMed  Google Scholar 

  44. Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol. 2015;22(5):1680–5.

    Article  PubMed  Google Scholar 

  45. Sugarbaker PH, Turaga KK, Alexander R, Deraco M, Hesdorffer M. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 2016;12(10):928–35.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Chicago University Hospital Medicine, Chicago, IL, USA

    Elizabeth Poli & Kiran K. Turaga

  2. Department of Surgical Oncology, CHL-CBCC Cancer Centre, Indore, India

    Ashvin Rangole

Authors
  1. Elizabeth Poli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashvin Rangole
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kiran K. Turaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashvin Rangole .

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, Fortis Hospital, Bangalore, India

    Aditi Bhatt

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Poli, E., Rangole, A., Turaga, K.K. (2018). Malignant Peritoneal Mesothelioma. In: Bhatt, A. (eds) Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond. Springer, Singapore. https://doi.org/10.1007/978-981-10-7053-2_15

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7053-2_15

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7052-5

  • Online ISBN: 978-981-10-7053-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation